← Human Trials & Peer-Reviewed Studies
Long-term effects of angiotensin II blockade with irbesartan on inflammatory markers in hemodialysis patients: A randomized double blind placebo controlled trial (SAFIR study).
Plain-language guide to PMID 27346437 (2017): double-blind randomized controlled trial of Angiotensin II.
Key Facts
- PMID
- 27346437
- Journal
- Hemodialysis international. International Symposium on Home Hemodialysis
- Year
- 2017
- Study type
- Randomized Controlled Trial
- Authors
- Peters CD et al. (7 authors)
- DOI
- 10.1111/hdi.12436
What This Study Did, in Plain Language
What Was Tested
Researchers studied Angiotensin II in this randomized controlled trial publication.
The aim of this study was to compare the effect of ARB vs. placebo on plasma concentrations of inflammatory markers in HD patients.
Why It Was Studied
Low-grade chronic inflammation is common in hemodialysis (HD) patients.
Who Took Part
PubMed indexes the participants as middle-aged adults, both men and women.
How the Study Was Run
The researchers set it up as a randomized, double-blind and placebo-controlled study.
The participants were allocated by chance, so the Angiotensin II group and the comparison group should start out alike.
Neither the participants nor the staff measuring them knew who was on Angiotensin II, so expectations could not easily colour the readings.
The comparison arm used a placebo, so changes seen with Angiotensin II could be set against what happens without it.
At baseline, 1 week, 3, 6, 9, and 12 months plasma high sensitivity C-reactive protein (hsCRP), interleukin (IL)-1β, IL-6, IL-8, IL-18, and transforming growth factor-β (TGF-β) were measured using Luminex and enzyme-linked immunosorbent assay (ELISA) technology.
What Was Measured
PubMed files the paper under topics including Angiotensin II Type 1 Receptor Blockers, Biomarkers, Biphenyl Compounds, Irbesartan, Renal Dialysis and Tetrazoles.
Author keywords: Angiotensin II blockade, cytokines, hemodialysis, inflammation and randomized controlled trial.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Angiotensin II.
Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2017 (Hemodialysis international. International Symposium on Home Hemodialysis), a journal based in Canada.
More context: the Angiotensin II compound page, all human trials.
Our Notes on the Compound
Angiotensin II: An 8-amino-acid hormone that narrows blood vessels; synthetic angiotensin II (Giapreza) is used for low blood pressure in shock.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.